Skip to main content
Clinical Trials/NCT00211653
NCT00211653
Completed
Phase 1

Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure

Minneapolis Veterans Affairs Medical Center1 site in 1 country102 target enrollmentApril 2003

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Kidney Failure
Sponsor
Minneapolis Veterans Affairs Medical Center
Enrollment
102
Locations
1
Primary Endpoint
Rise in creatinine above baseline
Status
Completed
Last Updated
18 years ago

Overview

Brief Summary

The purpose of this study is to determine if Acetylcysteine is effective in preventing renal failure associated with cardiac surgery

Detailed Description

Postoperative renal dysfunction is a predictor of significant morbidity and mortality among patients undergoing cardiac surgery. The mortality associated with coronary artery by-pass surgery increases from 2% to almost 19% in patients with renal failure and approaches 60% in patients who require hemodialysis. Patients with preoperative renal dysfunction referred for coronary artery by pass surgery have an extraordinarily high risk of requiring postoperative dialysis. For example, among those patients with preoperative creatinine \>2.5 mg/dL, almost 50% require hemodialysis. Comparison: N-Acetylcysteine is superior to placebo in preventing renal failure after cardiac surgery

Registry
clinicaltrials.gov
Start Date
April 2003
End Date
November 2006
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Minneapolis Veterans Affairs Medical Center

Eligibility Criteria

Inclusion Criteria

  • Pts with baseline chronic kidney disease (eGFR\<60 ml/min/1.73m2)undergoing cardiac surgery

Exclusion Criteria

  • Patients on hemodialysis preoperatively
  • IV contrast within 4 days prior to surgery
  • Urgent/emergent surgery
  • History of renal transplantation

Outcomes

Primary Outcomes

Rise in creatinine above baseline

Time Frame: 7 days postoperatively

Secondary Outcomes

  • Creatinine increase >25% or =/> 0.5 mg/dl above baseline(Postoperative days 5, 7 and 30)
  • Length of stay in the ICU and the hospital
  • Operative mortality(30-day)

Study Sites (1)

Loading locations...

Similar Trials